Our Company

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs. Our pharmaceutical strategy includes the development of investigational product candidates for the treatment of Amyloid A amyloidosis, Type II diabetes and certain features of metabolic syndrome, and Alzheimer’s disease. BELLUS Health’s strategic acquisition of Innodia Inc. provides access to additional expertise and rights in diabetes and obesity, helping to accelerate the Corporation’s own projects in diabetes and pipeline expansion through Innodia's identified candidate leads.

Pipeline Overview

BELLUS Health's pipeline contains promising therapeutic products at various stages of development aimed at providing innovative health solutions that address critical unmet medical needs and which have the potential to be large growth drivers.